QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advanced Cell Technology, Inc. (ACTC) Clinical Partner Gets FDA Approval To Commence Phase I/II Myopia Study 0 comments
    Feb 11, 2013 5:37 PM | about stocks: D

    2013 Advanced Cell Technology's clinical partner, the University of California, Los Angeles (UCLA), has received FDA approval of its Investigator Investigational New Drug (NYSE:IND) application, providing a green light for UCLA scientists to commence a phase I/II study using ACT's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat myopic macular degeneration (myopia), or nearsightedness.

    Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute, will initiate the 12-patient study to evaluate the safety in patients with severe myopia, which can lead to permanent vision loss.

    "We are encouraged by Dr. Schwartz's keen interest in the evaluation of ACT's RPE cells in potentially treating myopia," Gary Rabin, chairman and CEO of ACT stated in the press release. "We are pleased to be on track to broaden the scope of our RPE program with the initiation of the new Investigator IND. Nearsightedness is a very common condition, worldwide, and it is estimated that roughly 30 percent of cases are high, or severe, myopia."

    Dr. Schwartz is also the principal investigator in each of ACTC's two phase I/II clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD). He echoed the global need for the treatment for myopia.

    "We look forward to initiating the clinical trial," Dr. Schwartz stated. "Myopic degeneration is an increasingly important global cause of permanent central vision loss for which there is no accepted treatment. Applying our key learnings from the ongoing ACT-sponsored stem cell trials allows the research promise of regenerative medicine to include myopic vision loss."

    The myopia clinical trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with myopia at 12 months, the study's primary endpoint.

    For more information, visit advancedcell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: D
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.